Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which of it primarily is targeting Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, the Company is primarily targeting Parkinson's Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100 milligrams (mg) of resveratrol. It has a worldwide license, from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
Símbolo de cotizaciónJUNS
Nombre de la empresaJupiter Neurosciences Inc
Fecha de salida a bolsaDec 03, 2024
Fundada en2016
Director ejecutivoMr. Christer Rosen
Número de empleados4
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 03
Dirección1001 North US HWY 1, Suite 504
CiudadPALM BEACH GARDENS
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal33477
Teléfono15614066154
Sitio Webhttps://jupiterneurosciences.com/
Símbolo de cotizaciónJUNS
Fecha de salida a bolsaDec 03, 2024
Fundada en2016
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos